IL-17A-induced mesenchymal stem cells have promising therapeutic value for clinical translation.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 29571447.
- Also identified by DOI 10.1016/j.kint.2017.12.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interferon (IFN) gamma is the prototypic proinflammatory cytokine used to preactivate the immunomodulatory properties of mesenchymal stem cells (MSC). IFN-gamma, however, converts MSC into a cell therapy that can be immunogenic, detrimental, and hence nonfeasible for clinical application. The article by Bai et al. is an in vivo proof-of-concept study that interleukin-17A (IL-17A) enhances the immunosuppressive, tolerance-promoting, and renoprotective properties of MSC. IL-17A is an alternative cytokine to preactivate MSC. IL-17A enhances the therapeutic efficacy of MSC for renal diseases.
Medical subject headings
- Interleukin-17
- Mesenchymal Stem Cells